<DOC>
	<DOCNO>NCT00162136</DOCNO>
	<brief_summary>The purpose study determine dose limit toxicity , minimum tolerate dose recommend dose Phase II study .</brief_summary>
	<brief_title>Clinical Study Ixabepilone Administered 24 Hour Infusion Patients With Solid Malignancies .</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>confirm diagnosis primary solid tumor measurable nonmeasurable disease progressive disease men woman great equal 18 year age . woman child bear potential use birth control woman pregnant breast feed woman positive pregnancy test enrollment patient brain metastasis prior treatment Ixabepilone know history human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>